Condition
Neuroendocrine
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
150%
3 of 2 completed with results
Key Signals
3 with results67% success
Data Visualizations
Phase Distribution
5Total
P 1 (3)
P 2 (2)
Trial Status
Completed2
Unknown2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00688623Phase 2Completed
RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
NCT01169649Phase 2Completed
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
NCT01149434Phase 1Terminated
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
NCT02038738Phase 1UnknownPrimary
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
NCT00314925Phase 1Unknown
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
Showing all 5 trials